|
LIVE WEBINAR: Wednesday, February 3, 2021, 5:00 PM – 6:00 PM Eastern Time
Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and Presentations from the 62nd ASH Annual MeetingPart 2 - Hodgkin and Non-Hodgkin LymphomaFaculty
John Kuruvilla, MD Hematologist, Princess Margaret Cancer Centre Associate Professor, University of Toronto Toronto, Ontario, Canada John P Leonard, MD Richard T Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Executive Vice Chair, Joan and Sanford I Weill Department of Medicine Weill Cornell Medicine New York, New York Michael E Williams, MD, ScM Byrd S Leavell Professor of Medicine Chief, Hematology/Oncology Division Physician Lead, Cancer Service Line University of Virginia School of Medicine Charlottesville, Virginia Moderator Neil Love, MD Research To Practice Miami, Florida Wednesday, February 3, 2021 Topics to Be Discussed
Target Audience
CME Credit Form Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Kuruvilla — Consulting Agreements: AbbVie Inc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Roche Laboratories Inc, Seagen Inc; Honoraria: Amgen Inc, Antengene, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc, TG Therapeutics Inc. Dr Leonard — Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, MEI Pharma Inc, MorphoSys, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company. Dr Williams — Advisory Committee: AbbVie Inc; Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Speakers Bureau: Xian Janssen Pharmaceutical Ltd.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics and Seagen Inc. |